Reaktion #306314

ord-93b255c8d8a847ad88d25e6f4fb20e47

Reaktionsbedingungen

Temperatur
-45°CELSIUS
Detaillierte Bedingungen
See reaction.notes.procedure_details.

Aufarbeitung

  1. 1
    TemperaturThe mixture was then warmed up to rt
  2. 2
    workup.STIRRINGto stir for additional 30 minutes
  3. 3
    TemperaturThe reaction was warmed up to 50° C. for 6 h
  4. 4
    Sonstigewas quenched with 50 mL of satd
  5. 5
    ExtraktionThe mixture was extracted with 150 mL of EtOAc
  6. 6
    Waschenthe organic phase was washed with 60 mL of brine
  7. 7
    ExtraktionThe aqueous phases were extracted with 100 mL EtOAc again
  8. 8
    TrocknenThe combined organic phases were dried over Na2SO4
  9. 9
    Einengenconcentrated in vacuo
  10. 10
    SonstigeThe residue was purified by a silica gel column chromatography (EtOAc to 15% MeOH in EtOAc)

Vorschrift

To a solution of 5-bromo-3-methylisothiazole (1.00 g, 5.6 mmol) in 10 mL of THF at −45° C. (CH3CN/dry ice) was added isopropylmagnesium chloride LiCl complex (7.9 ml, 7.9 mmol) (LiCl complex, 1M in THF). The mixture was stirred at −45° C. for 20 minutes and was added zinc chloride, 0.5m in the (17 ml, 8.4 mmol) slowly via a syringe. The mixture was then warmed up to rt and continued to stir for additional 30 minutes. 6-(1-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (0.5787 g, 1.9 mmol), tris(dibenzylideneacetone)dipalladium (o) (0.51 g, 0.56 mmol) and Q-Phos (0.65 g) in 15 mL of N,N-dimethyl acetamide was added to the reaction mixture. The reaction was warmed up to 50° C. for 6 h and was quenched with 50 mL of satd. NH4Cl aq. solution. The mixture was extracted with 150 mL of EtOAc and the organic phase was washed with 60 mL of brine. The aqueous phases were extracted with 100 mL EtOAc again. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. The residue was purified by a silica gel column chromatography (EtOAc to 15% MeOH in EtOAc) to give red solid as desired product 6-(1-(6-(3-methylisothiazol-5-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline. MS (ESI, pos. ion) m/z: 373.2 (M+1).

Quelle

DOI: 10.6084/m9.figshare.5104873.v1Patent: US08198448B2uspto-grants-2012_06